Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) EBITDA Margin (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed EBITDA Margin for 7 consecutive years, with 18.56% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin rose 4628.0% to 18.56% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 31.31% through Dec 2025, up 24508.0% year-over-year, with the annual reading at 31.31% for FY2025, 24508.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 18.56% at Madrigal Pharmaceuticals, up from 39.68% in the prior quarter.
  • The five-year high for EBITDA Margin was 18.56% in Q4 2025, with the low at 1110.38% in Q2 2024.